Trials / Recruiting
RecruitingNCT04787471
Corneal Crosslinking for Treatment of Corneal Neovascularization
Randomized Comparison of Standard vs. Accelerated Corneal Crosslinking for Treatment of Corneal Neovascularization With or Without Concomitant Inflammation and/or Infection
- Status
- Recruiting
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 62 (estimated)
- Sponsor
- Price Vision Group · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The study objective is to assess safety and efficacy of photo-activation of riboflavin for treatment of corneal neovascularization with or without concomitant inflammation and/or infection.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| COMBINATION_PRODUCT | 30 minute photoactivation of riboflavin 0.1% | Use of riboflavin 0.1% eye drops and 3mW/cm2 UVA light for 30 minutes |
| COMBINATION_PRODUCT | 10 minute photoactivation of riboflavin 0.1% | Use of riboflavin 0.1% eye drops and 9mW/cm2 UVA light for 10 minutes |
Timeline
- Start date
- 2021-05-03
- Primary completion
- 2026-07-15
- Completion
- 2026-09-15
- First posted
- 2021-03-08
- Last updated
- 2025-07-31
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04787471. Inclusion in this directory is not an endorsement.